325 related articles for article (PubMed ID: 27357286)
21. CSF complement 3 and factor H are staging biomarkers in Alzheimer's disease.
Hu WT; Watts KD; Tailor P; Nguyen TP; Howell JC; Lee RC; Seyfried NT; Gearing M; Hales CM; Levey AI; Lah JJ; Lee EK;
Acta Neuropathol Commun; 2016 Feb; 4():14. PubMed ID: 26887322
[TBL] [Abstract][Full Text] [Related]
22. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
Wang S; Zhang J; Pan T;
Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
[TBL] [Abstract][Full Text] [Related]
23. Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.
Elias-Sonnenschein LS; Helisalmi S; Natunen T; Hall A; Paajanen T; Herukka SK; Laitinen M; Remes AM; Koivisto AM; Mattila KM; Lehtimäki T; Verhey FR; Visser PJ; Soininen H; Hiltunen M
PLoS One; 2013; 8(4):e59676. PubMed ID: 23573206
[TBL] [Abstract][Full Text] [Related]
24. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
Wattmo C; Blennow K; Hansson O
BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
[TBL] [Abstract][Full Text] [Related]
25. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
26. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer's disease.
Wang L; Gao T; Cai T; Li K; Zheng P; Liu J;
Neurosci Lett; 2020 Jan; 715():134658. PubMed ID: 31794792
[TBL] [Abstract][Full Text] [Related]
28. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K;
Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100
[TBL] [Abstract][Full Text] [Related]
29. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients.
Gabriel AJ; Almeida MR; Ribeiro MH; Durães J; Tábuas-Pereira M; Pinheiro AC; Pascoal R; Santana I; Baldeiras I
Neurosci Lett; 2017 Feb; 641():101-106. PubMed ID: 28108398
[TBL] [Abstract][Full Text] [Related]
30. Association of APOE-ε4 and GAP-43-related presynaptic loss with β-amyloid, tau, neurodegeneration, and cognitive decline.
Lan G; Du J; Chen X; Wang Q; ; Han Y; Guo T
Neurobiol Aging; 2023 Dec; 132():209-219. PubMed ID: 37852045
[TBL] [Abstract][Full Text] [Related]
31. Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
Saddiki H; Fayosse A; Cognat E; Sabia S; Engelborghs S; Wallon D; Alexopoulos P; Blennow K; Zetterberg H; Parnetti L; Zerr I; Hermann P; Gabelle A; Boada M; Orellana A; de Rojas I; Lilamand M; Bjerke M; Van Broeckhoven C; Farotti L; Salvadori N; Diehl-Schmid J; Grimmer T; Hourregue C; Dugravot A; Nicolas G; Laplanche JL; Lehmann S; Bouaziz-Amar E; ; Hugon J; Tzourio C; Singh-Manoux A; Paquet C; Dumurgier J
PLoS Med; 2020 Aug; 17(8):e1003289. PubMed ID: 32817639
[TBL] [Abstract][Full Text] [Related]
32. Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.
Zetterberg M; Landgren S; Andersson ME; Palmér MS; Gustafson DR; Skoog I; Minthon L; Thelle DS; Wallin A; Bogdanovic N; Andreasen N; Blennow K; Zetterberg H
Am J Med Genet B Neuropsychiatr Genet; 2008 Sep; 147B(6):720-6. PubMed ID: 18163432
[TBL] [Abstract][Full Text] [Related]
33. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.
Benitez BA; Karch CM; Cai Y; Jin SC; Cooper B; Carrell D; Bertelsen S; Chibnik L; Schneider JA; Bennett DA; ; ; Fagan AM; Holtzman D; Morris JC; Goate AM; Cruchaga C
PLoS Genet; 2013; 9(8):e1003685. PubMed ID: 23990795
[TBL] [Abstract][Full Text] [Related]
34. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
Tosun D; Schuff N; Truran-Sacrey D; Shaw LM; Trojanowski JQ; Aisen P; Peterson R; Weiner MW;
Neurobiol Aging; 2010 Aug; 31(8):1340-54. PubMed ID: 20570401
[TBL] [Abstract][Full Text] [Related]
35. APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease.
Konijnenberg E; Tijms BM; Gobom J; Dobricic V; Bos I; Vos S; Tsolaki M; Verhey F; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Frölich L; Lovestone S; Streffer J; Bertram L; Blennow K; Teunissen CE; Veerhuis R; Smit AB; Scheltens P; Zetterberg H; Visser PJ
Alzheimers Res Ther; 2020 May; 12(1):65. PubMed ID: 32460813
[TBL] [Abstract][Full Text] [Related]
36. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
37. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.
Ott BR; Cohen RA; Gongvatana A; Okonkwo OC; Johanson CE; Stopa EG; Donahue JE; Silverberg GD;
J Alzheimers Dis; 2010; 20(2):647-57. PubMed ID: 20182051
[TBL] [Abstract][Full Text] [Related]
38. Interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
Osorio RS; Ayappa I; Mantua J; Gumb T; Varga A; Mooney AM; Burschtin OE; Taxin Z; During E; Spector N; Biagioni M; Pirraglia E; Lau H; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Rapoport DM; de Leon MJ
Neurobiol Aging; 2014 Jun; 35(6):1318-24. PubMed ID: 24439479
[TBL] [Abstract][Full Text] [Related]
39. Diabetes mellitus contributes to higher cerebrospinal fluid tau levels selectively in Alzheimer's disease patients with the APOE4 genotype.
Motta C; Assogna M; Bonomi CG; Mascolo AP; De Lucia V; Semprini R; Mercuri NB; Koch G; Martorana A
Eur J Neurol; 2021 Dec; 28(12):3965-3971. PubMed ID: 34309155
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
